NKTR

Nektar Therapeutics

37.26

Nov 06 • 3:59 PM ET +1.11 (3.07%)

37.26

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: ATTO EVMN QTTB KYMR MANE ORKA REGN ARQT IMCR COYA

| Held by: VTI XBI IWM VXF VTWO IWO SCHA VHT VTWG LFSC

Scroll to Statements

Index	RUT
Market Cap	1.27B
Enterprise Value	723.76M
Income	-157.13M
Sales	54.59M
Book/sh	26.46
Cash/sh	20.04
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	63
IPO	May 03, 1994

P/E	-
Forward P/E	-
PEG	-
P/S	23.30
P/B	1.41
P/C	1.86
P/FCF	-
EV/EBITDA	-
EV/Sales	13.26
Quick Ratio	10.42
Current Ratio	10.42
Debt/Eq	0.15
LT Debt/Eq	0.13
Option/Short	Yes / Yes

EPS (ttm)	-6.70
EPS next Y	-10.50
EPS next Q	-2.07
EPS this Y	16.92%
EPS next Y	-29.95%
EPS next 5Y	-3.29%
EPS past 3/5Y	30.93% 23.59%
Sales past 3/5Y	-15.66% -18.43%
EPS Y/Y TTM	23.10%
Sales Y/Y TTM	-27.15%
EPS Q/Q	58.38%
Sales Q/Q	-9.34%
Earnings	Nov 12 AMC
EPS/Sales Surpr.	37.60% -2.82%

Insider Own	3.21%
Insider Trans	-2.88%
Inst Own	103.82%
Inst Trans	28.94%
ROA	-24.12%
ROE	-35.75%
ROIC	-15.46%
Gross Margin	98.73%
Oper. Margin	-239.32%
Profit Margin	-287.84%
SMA20	-1.53%
SMA50	-28.34%
SMA200	-42.70%
Trades

Shs Outstand	34.13M
Shs Float	33.05M
Short Float	21.17%
Short Ratio	6.42
Short Interest	7.00M
52W High	109.00 -65.82%
52W Low	33.40 11.56%
Volatility	4.82% 4.56%
ATR (14)	2.18
RSI (14)	36.36
Beta	1.43
Rel Volume	0.63
Avg Volume	1.09M
Volume	686,549

Perf Week	-4.14%
Perf Month	-8.68%
Perf Quarter	-50.23%
Perf Half Y	-54.50%
Perf YTD	-11.87%
Perf Year	-32.40%
Perf 3Y	368.86%
Perf 5Y	-81.53%
Perf 10Y	-79.80%
Recom	1.53
Target Price	133.08
Prev Close	36.15
Price	37.26
Change %	3.07%

Consensus

Buy

Avg. Price Target

$133.08

Implied Upside

+257.2%

Analysts16incl. previous ratings

Rating Distribution12 Buy · 4 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 12, 2026	Initiated	UUBS	Neutral	$53	+42.2%
Oct 12, 2026	Initiated	LLeerink Partners	Outperform	$130	+248.9%
Oct 09, 2026	Initiated	RRaymond James	Mkt Perform
Aug 21, 2026	Resumed	JJP Morgan	Neutral	$65	+74.4%
Jul 22, 2026	Initiated	CCanaccord Genuity	Buy	$153	+310.6%
Mar 24, 2026	Initiated	WWedbush	Neutral	$70	+87.9%
Mar 17, 2026	Initiated	TTD Cowen	Buy
Feb 10, 2026	Upgrade	WWilliam Blair	Mkt Perform → Outperform
Nov 26, 2025	Initiated	CCitigroup	Buy	$102	+173.8%
Jun 24, 2025	Reiterated	HH.C. Wainwright	Buy	$6.50 → $120	+222.1%
Jun 24, 2025	Reiterated	BBTIG Research	Buy	$60 → $100	+168.4%
Apr 11, 2025	Upgrade	JJefferies	Hold → Buy	$2	-94.6%
Mar 14, 2025	Upgrade	OOppenheimer	Perform → Outperform	$6	-83.9%
Jan 08, 2025	Initiated	RB. Riley Securities	Buy	$4	-89.3%
Dec 10, 2024	Initiated	HH.C. Wainwright	Buy	$6.50	-82.6%
Nov 04, 2024	Initiated	PPiper Sandler	Overweight	$7	-81.2%
Sep 30, 2024	Resumed	BBTIG Research	Buy	$4	-89.3%
Jun 28, 2024	Initiated	RRodman & Renshaw	Buy	$2	-94.6%
Nov 20, 2023	Resumed	JJP Morgan	Underweight
Nov 09, 2023	Upgrade	TTD Cowen	Market Perform → Outperform

Nov-04-26 06:10PM	Nektar Reports With Shares Halved, Phase 3 Spending Rising And A Jury Trial To Explain (Earnings Whispers) -6.06%
Oct-27-26 06:00PM	Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets (PR Newswire)
Oct-23-26 04:15PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Oct-05-26 07:57AM	EADV26: Key late-stage readouts from the conference (Clinical Trials Arena)
Oct-01-26 04:34PM	Nektar Posted Promising Alopecia Results. Here's Why It Took A 22% Beating. (Investor's Business Daily) -22.39% -7.26%
03:42PM	Loading…
03:42PM	NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge (Stocktwits)
11:45AM	Nektar Stock Sinks Despite Promising Hair Loss Treatment Data (Barrons.com)
11:44AM	3 Biotech Stocks Put Traders Are Targeting Today (Schaeffer's Research)
07:30AM	New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 (PR Newswire)
Sep-30-26 10:30AM	New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis (PR Newswire)
Sep-28-26 08:00AM	Nektar Announces Three Oral Presentations for Rezpegaldesleukin at the European Academy of Dermatology & Venereology (EADV) Congress 2026 (PR Newswire) +5.85%
02:32AM	Eli Lilly Wins FDA Approval for Weekly Insulin. Heres What Comes Next (TIKR)
Sep-26-26 08:32AM	A Jury Awarded Nektar $90 Million From Eli Lilly. Heres Why the Stock Barely Moved (TIKR)
Sep-25-26 04:15PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +5.85%
09:47AM	Nektar Therapeutics stock rises on $90M jury verdict vs Lilly (Investing.com)
09:21AM	Loading…
09:21AM	Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimers data (BioPharma Dive)
Aug-28-26 04:15PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-25-26 08:30AM	Nektar Announces Publication in The Lancet of Positive Phase 2b REZOLVE-AD 16-Week Induction Results of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis (PR Newswire)
Aug-14-26 01:01AM	Nektar Therapeutics (NKTR) (Q2 2026) Earnings Call Highlights: Respeg Phase 3 Momentum and ... (GuruFocus.com)
Aug-13-26 04:32PM	Nektar: Q2 Earnings Snapshot (Associated Press)
04:15PM	Nektar Therapeutics Announces Second Quarter 2026 Financial Results (PR Newswire)
Jul-28-26 06:00PM	Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets (PR Newswire)
Jul-24-26 04:15PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jul-21-26 07:00AM	Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis (PR Newswire) +5.91%
Jul-02-26 08:41PM	NKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In Eczema (Stocktwits) +10.33%
Jun-26-26 04:30PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-03-26 04:15PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-27-26 06:15PM	Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York (PR Newswire)
May-07-26 05:18PM	Nektar: Q1 Earnings Snapshot (Associated Press)
04:15PM	Nektar Therapeutics Reports First Quarter 2026 Financial Results (PR Newswire)
04:39PM	Loading…
May-01-26 04:39PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-28-26 06:00PM	Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets (PR Newswire)
Apr-23-26 04:15PM	Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Apr-21-26 09:30PM	Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering (PR Newswire) -5.05%
Apr-20-26 04:01PM	Nektar Therapeutics Announces Proposed Public Offering (PR Newswire) +18.25%
02:34PM	Market Feels Weak, But Stocks Tell Stories (GuruFocus.com)
12:43PM	Nektar Therapeutics Adds To Its 129% Two-Month Run With Alopecia News (Investor's Business Daily)
11:43AM	This Biotech Stock Soars on Hair Loss Trial Results. It's Not a Cure for Baldness. (Barrons.com)
08:01AM	Nektar surges again as alopecia drug shows new promise in extension study (BioPharma Dive)
07:30AM	52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin (PR Newswire)
Apr-19-26 12:00PM	Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026 (PR Newswire)
Mar-28-26 12:36PM	Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting (PR Newswire)
Mar-27-26 10:34AM	Short Squeeze Stocks: The Usual Suspects, & One Newcomer (Schaeffer's Research)
Mar-23-26 08:15AM	Apogee strengthens case for longer-lasting eczema drug (BioPharma Dive)
Mar-20-26 10:00AM	Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting (PR Newswire)
Mar-17-26 09:33AM	DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls (The Fly)
Mar-16-26 03:09AM	Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR (PR Newswire)
Mar-12-26 11:05PM	Nektar Therapeutics (NKTR) Q4 2025 Earnings Call Highlights: Promising Phase 2B Results and ... (GuruFocus.com)
04:41PM	Nektar: Q4 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results (PR Newswire)
Mar-10-26 08:30AM	Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights NKTR (Business Wire)
07:10AM	Esperion Therapeutics (ESPR) Misses Q4 Earnings Estimates (Zacks)
Mar-06-26 06:00PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Mar-05-26 10:00AM	Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-26-26 06:00PM	Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets (PR Newswire) -6.35%
Feb-25-26 09:55AM	Wall Street Analysts Think Nektar (NKTR) Could Surge 89.8%: Read This Before Placing a Bet (Zacks)
Feb-24-26 06:00PM	Nektar Therapeutics to Participate in Two Investor Conferences in March (PR Newswire) -7.06%
Feb-23-26 12:07PM	GeneDx Q4 Earnings Call Highlights (MarketBeat)
Feb-17-26 07:00AM	Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis (PR Newswire)
Feb-13-26 04:15PM	Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Feb-11-26 10:23PM	Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering (PR Newswire) +18.48% +7.01%
08:08AM	Nektar (NKTR) Soars 51.1%: Is Further Upside Left in the Stock? (Zacks)
07:42AM	Nektars stock rises 51% on Phase II Rezpeg AD maintenance win (Clinical Trials Arena)
07:35AM	Why Is Nektar Therapeutics Stock Gaining Wednesday? (Benzinga)
02:07AM	Nektar Therapeutics Touts 52-Week ResPEG Data in Atopic Dermatitis, Eyes Phase 3 Launch in Q2 (MarketBeat)
Feb-10-26 04:07PM	Has Dupixent Met Its Match? Rivals Nektar, Evommune Catapult On Eczema Results. (Investor's Business Daily) +51.07%
04:05PM	Nektar Therapeutics Announces Proposed Public Offering (PR Newswire)
11:57AM	Nektar Therapeutics Stock Is Trending Tuesday: What's Going On? (Benzinga)
07:13AM	Nektar, continuing comeback, says eczema drugs effects hold up in follow-up study (BioPharma Dive)
07:00AM	New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing (PR Newswire)
Feb-09-26 04:15PM	Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026 (PR Newswire)
Feb-02-26 10:02PM	Nektar Therapeutics (NKTR): A Bull Case Theory (Insider Monkey)
Jan-30-26 04:10PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +5.96%
Jan-08-26 09:36AM	Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics (Zacks)
Jan-07-26 08:45AM	5 Small Drug Stocks to Buy as Industry Recovery Picks Up (Zacks)
Jan-05-26 05:05PM	Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead (Motley Fool)
Dec-26-25 02:33AM	The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar (Zacks)
Dec-24-25 10:51AM	4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow (Zacks)
Dec-21-25 07:31AM	Strong REZOLVE-AA Study Results Drive Analyst Confidence in Nektar Therapeutics (NKTR) (Insider Monkey)
Dec-16-25 07:30AM	REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata (PR Newswire) -7.77%
06:24AM	Nektar sees silver lining as autoimmune drug narrowly misses in alopecia study (BioPharma Dive)
Dec-15-25 06:00PM	Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025 (PR Newswire)
Dec-08-25 12:00PM	Here's Why Nektar Therapeutics (NKTR) is a Great Momentum Stock to Buy (Zacks)
Dec-05-25 06:00PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-01-25 09:55AM	Wall Street Analysts Believe Nektar (NKTR) Could Rally 64.53%: Here's is How to Trade (Zacks) -6.29%
Nov-26-25 09:43AM	Autodesk upgraded, Nio downgraded: Wall Street's top analyst calls (The Fly) +8.85%
Nov-23-25 07:02AM	Is Nektar Therapeutics (NKTR) The Hottest SMID-Cap Stock to Buy Now? (Insider Monkey)
Nov-20-25 06:57AM	Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. (Motley Fool) -8.68%
Nov-13-25 09:55AM	Does Nektar (NKTR) Have the Potential to Rally 62.75% as Wall Street Analysts Expect? (Zacks) -6.45%
Nov-08-25 05:45PM	New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting (PR Newswire)
Nov-07-25 10:11AM	Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
12:07AM	Nektar Therapeutics (NKTR) Q3 2025 Earnings Call Highlights: Strong Cash Position and Promising ... (GuruFocus.com)
Nov-06-25 05:55PM	Nektar Therapeutics (NKTR) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
05:06PM	Nektar: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Third Quarter 2025 Financial Results (PR Newswire)
Nov-03-25 10:00AM	Guardian Pharmacy Services (GRDN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks) -7.72%
Oct-30-25 06:00PM	Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London (PR Newswire) +5.32%
10:00AM	Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-28-25 06:00PM	Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets (PR Newswire)
09:55AM	Wall Street Analysts See a 50.01% Upside in Nektar (NKTR): Can the Stock Really Move This High? (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zalevsky Jonathan	Chief R&D Officer	Aug 18 '26	Sale	71.98	186	13,388	9,570	Aug 20 07:05 PM
ROBIN HOWARD W	President & CEO	Aug 18 '26	Sale	71.98	418	30,088	54,627	Aug 20 07:03 PM
Zalevsky Jonathan	Officer	Aug 18 '26	Proposed Sale	71.98	186	13,388		Aug 18 03:57 PM
ROBIN HOWARD W	Officer	Aug 18 '26	Proposed Sale	71.98	418	30,087		Aug 18 03:42 PM
Zalevsky Jonathan	Chief R&D Officer	Jun 30 '26	Sale	70.00	5,681	397,670	9,756	Jul 02 07:06 PM
JONATHAN ZALEVSKY	Officer	Jun 30 '26	Proposed Sale	65.39	5,681	371,481		Jun 30 04:36 PM
ROBIN HOWARD W	President & CEO	Jun 17 '26	Sale	61.19	10,000	611,880	55,045	Jun 18 07:08 PM
ROBIN HOWARD W	President & CEO	Jun 16 '26	Sale	60.32	10,000	603,176	65,045	Jun 18 07:08 PM
Zalevsky Jonathan	Chief R&D Officer	Jun 15 '26	Sale	60.71	5,538	336,212	15,437	Jun 17 07:12 PM
ROBIN HOWARD W	Officer	Jun 17 '26	Proposed Sale	60.27	10,000	602,700		Jun 17 11:05 AM
ROBIN HOWARD W	Officer	Jun 16 '26	Proposed Sale	60.96	10,000	609,600		Jun 16 11:07 AM
JONATHAN ZALEVSKY	Officer	Jun 15 '26	Proposed Sale	59.38	5,538	328,846		Jun 15 04:56 PM
Zalevsky Jonathan	Chief R&D Officer	May 19 '26	Sale	65.51	199	13,036	20,975	May 21 06:26 PM
ROBIN HOWARD W	President & CEO	May 19 '26	Sale	65.51	444	29,086	75,045	May 21 06:26 PM
Zalevsky Jonathan	Officer	May 19 '26	Proposed Sale	65.51	199	13,036		May 19 03:27 PM
ROBIN HOWARD W	Officer	May 19 '26	Proposed Sale	65.51	444	29,085		May 19 03:24 PM
Wilson Mark Andrew	Former Officer	Mar 13 '26	Proposed Sale	72.64	78,510	5,702,966		Mar 13 01:04 PM
Zalevsky Jonathan	Chief R&D Officer	Feb 18 '26	Sale	73.00	180	13,140	21,174	Feb 20 07:10 PM
ROBIN HOWARD W	President & CEO	Feb 18 '26	Sale	73.00	423	30,879	75,489	Feb 20 07:10 PM
ROBIN HOWARD W	Officer	Feb 18 '26	Proposed Sale	73.00	423	30,878		Feb 18 03:47 PM
Zalevsky Jonathan	Officer	Feb 18 '26	Proposed Sale	73.00	180	13,140		Feb 18 03:15 PM
Zalevsky Jonathan	Chief R&D Officer	Jan 20 '26	Sale	35.67	3,867	137,936	21,354	Jan 22 07:31 PM
Zalevsky Jonathan	Officer	Jan 20 '26	Proposed Sale	35.67	3,867	137,946		Jan 20 04:21 PM
Zalevsky Jonathan	Chief R&D Officer	Nov 25 '25	Sale	54.28	1,157	62,802	18,971	Nov 25 08:30 PM
Wilson Mark Andrew	Chief Legal Officer	Nov 25 '25	Sale	54.28	630	34,196	21,585	Nov 25 08:29 PM
ROBIN HOWARD W	President & CEO	Nov 25 '25	Sale	54.28	2,207	119,796	54,245	Nov 25 08:28 PM
ROBIN HOWARD W	Officer	Nov 25 '25	Proposed Sale	58.82	2,207	129,812		Nov 25 03:35 PM
Wilson Mark Andrew	Officer	Nov 25 '25	Proposed Sale	58.82	630	37,056		Nov 25 03:32 PM
Zalevsky Jonathan	Officer	Nov 25 '25	Proposed Sale	58.82	1,157	68,053		Nov 25 03:28 PM

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

CEOMr. Howard W. Robin

Senior VP and Chief Research & Development OfficerDr. Jonathan Zalevsky Ph.D.

CFO and Principal Financial & Accounting OfficerMs. Linda M. Rubinstein M.A.

Chief Accounting OfficerMr. Jason Barnard

VP of LegalMs. Elizabeth Zhang

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NKTR

Nektar Therapeutics

Upgrade your Finviz experience